Krisztina Bogos

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.1K citations

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pharmacology +6

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 662 citations · Full text

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pathology +6

Identification and Clinical Significance of Circulating Endothelial Progenitor Cells in Human Non–Small Cell Lung Cancer

Balázs Döme, Judit Dobos, Lívia S. Mészáros et al. · Cancer Research · 2006 · 181 citations

The role of TTF-1 in differentiating primary and metastatic lung adenocarcinomas

Judit Moldvay, Márta Jäckel, Krisztina Bogos et al. · Pathology & Oncology Research · 2004 · 133 citations

Cancer Research, Metastatic Lung Adenocarcinomas, Medicine +8

Expression patterns and prognostic relevance of subtype‐specific transcription factors in surgically resected small‐cell lung cancer: an international multicenter study

Zsolt Megyesfalvi, Nándor Bárány, András Lantos et al. · The Journal of Pathology · 2022 · 80 citations · Full text